yes great they have a f2f meet, a timeline and on track to commence trial mid year. not so great that I think many would have been expecting to have this resolved by now. It'll be interesting to see markets reaction today.
- Forums
- ASX - By Stock
- Ann: Type C Meeting granted by FDA for Phelan-McDermid syndrome
NEU
neuren pharmaceuticals limited
Add to My Watchlist
7.50%
!
$13.48

yes great they have a f2f meet, a timeline and on track to...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$13.48 |
Change
0.940(7.50%) |
Mkt cap ! $1.692B |
Open | High | Low | Value | Volume |
$12.96 | $14.00 | $12.91 | $15.38M | 1.123M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 325 | $13.47 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.49 | 114 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 15 | 13.480 |
10 | 198 | 13.470 |
3 | 149 | 13.460 |
3 | 237 | 13.450 |
2 | 797 | 13.440 |
Price($) | Vol. | No. |
---|---|---|
13.500 | 1205 | 4 |
13.510 | 526 | 3 |
13.520 | 1116 | 4 |
13.530 | 4230 | 8 |
13.540 | 1072 | 3 |
Last trade - 15.09pm 26/06/2025 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
PTX
PRESCIENT THERAPEUTICS LIMITED
James McDonnell, CEO
James McDonnell
CEO
Previous Video
Next Video
SPONSORED BY The Market Online